Nasal steroid sprays side effects

March 11, 2017
Side Effects of Flonase

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adults and adolescents 12 years of age and older

In controlled US and international clinical studies, a total of 3210 adult and adolescent patients 12 years and older with allergic rhinitis received treatment with NASONEX (mometasone furoate (nasal spray)) Nasal Spray 50 mcg at doses of 50 to 800 mcg/day. The majority of patients (n = 2103) were treated with 200 mcg/day. A total of 350 adult and adolescent patients have been treated for one year or longer. Adverse events did not differ significantly based on age, sex, or race. Four percent or less of patients in clinical trials discontinued treatment because of adverse events and the discontinuation rate was similar for the vehicle and active comparators.

All adverse events (regardless of relationship to treatment) reported by 5% or more of adult and adolescent patients ages 12 years and older who received NASONEX (mometasone furoate (nasal spray)) Nasal Spray 50 mcg, 200 mcg/day vs. placebo and that were more common with NASONEX (mometasone furoate (nasal spray)) Nasal Spray 50 mcg than placebo, are displayed in TABLE 1 below.

TABLE 1: ADULT AND ADOLESCENT PATIENTS 12 YEARS AND OLDER - ADVERSE EVENTS FROM CONTROLLED CLINICAL TRIALS IN SEASONAL ALLERGIC AND PERENNIAL ALLERGIC RHINITIS (PERCENT OF PATIENTS REPORTING)

NASONEX (mometasone furoate (nasal spray))
200 mcg
(n = 2103)
VEHICLE PLACEBO
(n = 1671)
Headache 26 22
Viral Infection 14 11
Pharyngitis 12 10
Epistaxis/Blood-Tinged Mucus
Coughing
Upper Respiratory Tract Infection
Dysmenorrhea
Musculoskeletal Pain
Sinusitis

Other adverse events which occurred in less than 5% but greater than or equal to 2% of adult and adolescent patients (ages 12 years and older) treated with NASONEX (mometasone furoate (nasal spray)) Nasal Spray 50 mcg, 200-mcg/day (regardless of relationship to treatment), and more frequently than in the placebo group included: arthralgia, asthma, bronchitis, chest pain, conjunctivitis, diarrhea, dyspepsia, earache, flu-like symptoms, myalgia, nausea, and rhinitis.

Pediatric patients < 12 years of age

In controlled US and international studies, a total of 990 pediatric patients (ages 3 to 11 years) with allergic rhinitis received treatment with NASONEX (mometasone furoate (nasal spray)) Nasal Spray 50 mcg, at doses of 25 to 200 mcg/day. The majority of pediatric patients (n = 720) were treated with 100 mcg/day. A total of 163 pediatric patients have been treated for one year or longer. Two percent or less of patients in clinical trials who received NASONEX (mometasone furoate (nasal spray)) Nasal Spray 50 mcg discontinued treatment because of adverse events and the discontinuation rate was similar for the placebo and active comparators.

Adverse events which occurred in 55% of pediatric patients (ages 3 to 11 years) treated with NASONEX (mometasone furoate (nasal spray)) Nasal Spray 50 mcg, 100 mcg/day vs. placebo (regardless of relationship to treatment) and more frequently than in the placebo group included upper respiratory tract infection (5% in NASONEX (mometasone furoate (nasal spray)) Nasal Spray 50 mcg group vs. 4% in placebo) and vomiting (5% in NASONEX (mometasone furoate (nasal spray)) Nasal Spray 50 mcg group vs. 4% in placebo).

Other adverse events which occurred in less than 5% but greater than or equal to 2% of pediatric patients (ages 3 to 11 years) treated NASONEX (mometasone furoate (nasal spray)) Nasal Spray 50 mcg, 100 mcg/day vs. placebo (regardless of relationship to treatment) and more frequently than in the placebo group included: diarrhea, nasal irritation, otitis media, and wheezing.

The adverse event (regardless of relationship to treatment) reported by 5% of pediatric patients ages 2 to 5 years who received NASONEX (mometasone furoate (nasal spray)) Nasal Spray, 50 mcg, 100 mcg/day in a clinical trial vs. placebo including 56 subjects (28 each NASONEX (mometasone furoate (nasal spray)) Nasal Spray, 50 mcg and placebo) and that was more common with NASONEX (mometasone furoate (nasal spray)) Nasal Spray, 50 mcg than placebo, included: upper respiratory tract infection (7% vs. 0%, respectively). The other adverse event which occurred in less than 5% but greater than or equal to 2% of mometasone furcate pediatric patients ages 2 to 5 years treated with 100 mcg doses vs. placebo (regardless of relationship to treatment) and more frequently than in the placebo group included: skin trauma.

Source: www.rxlist.com
INTERESTING VIDEO
Corticosteroid nasal irrigations after endoscopic sinus
Corticosteroid nasal irrigations after endoscopic sinus ...
fluticasone propionate side effects
fluticasone propionate side effects
Vicks Nasal Spray Addiction Can It Make You Addicted
Vicks Nasal Spray Addiction Can It Make You Addicted

INTERESTING FACTS
Share this Post